Ye Ziheng, Xia Xiaotian, Xu Peipei, Liu Wenfei, Wang Shoufei, Fan Youben, Guo Minggao
Center of Thyroid and Parathyroid, Department of Thyroid, Parathyroid, Breast and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yi-Shan Road, Shanghai 200233, China.
Int J Endocrinol. 2022 Jun 16;2022:6562149. doi: 10.1155/2022/6562149. eCollection 2022.
The BRAF V600E mutation is an important genetic event in papillary thyroid cancer (PTC). This study aimed to provide additional information regarding the association of the BRAF V600E mutation with PTC prognosis.
A retrospective single-center study based on a Chinese population was performed to analyze the association of the BRAF V600E mutation with several clinicopathological features. Kaplan-Meier survival curves and Cox proportional hazards regression analysis were applied to implement the survival analysis.
The BRAF V600E mutation was present in 1102 (87.7%) of the 1257 patients and was significantly associated with older age, conventional subtype, multifocality, advanced TNM stage, and a reduced prevalence of Hashimoto's thyroiditis. The Kaplan-Meier survival curves demonstrated that the difference between the BRAF V600E-positive and BRAF V600E-negative groups was significant with a log-rank -value of 0.048. The Cox proportional hazards regression analysis adjusted HR was 3.731 (95% CI, 1.457 to 9.554). We further demonstrated that larger tumor size (>1 cm), extrathyroidal extension (ETE), and lateral lymph node metastasis (LNM) were associated with a higher probability of PTC recurrence in patients harboring the BRAF V600E mutation.
The BRAF V600E mutation remains an independent risk factor for PTC recurrence and may be useful for clinical decisions when it combines with some pathological factors.
BRAF V600E突变是甲状腺乳头状癌(PTC)中的一个重要遗传事件。本研究旨在提供关于BRAF V600E突变与PTC预后关联的更多信息。
进行了一项基于中国人群的回顾性单中心研究,以分析BRAF V600E突变与几种临床病理特征的关联。应用Kaplan-Meier生存曲线和Cox比例风险回归分析进行生存分析。
1257例患者中有1102例(87.7%)存在BRAF V600E突变,且该突变与年龄较大、经典亚型、多灶性、TNM分期较晚以及桥本甲状腺炎患病率降低显著相关。Kaplan-Meier生存曲线显示,BRAF V600E阳性组和BRAF V600E阴性组之间的差异具有统计学意义,对数秩检验P值为0.048。Cox比例风险回归分析调整后的HR为3.731(95%CI,1.457至9.554)。我们进一步证明,肿瘤较大(>1 cm)、甲状腺外侵犯(ETE)和侧方淋巴结转移(LNM)与携带BRAF V600E突变的PTC患者复发概率较高相关。
BRAF V600E突变仍然是PTC复发的独立危险因素,当与某些病理因素结合时可能有助于临床决策。